Inflammatory Bowel Disease (IBD) refers to a chronic and relapsing inflammatory disorder of the gastrointestinal tract GIT accompanied by abdominal pain, rectal bleeding and malabsorption. It comprises two major entities, ulcerative colitis UC and Crohn's disease CD.
Serologic panels of multiple antibodies are proposed to aid in differential diagnosis of CD versus UC in stratifying patients according to disease phenotype and risk of complications.
Fecal calprotectin testing may be considered medically necessary for ANY of the following:
Fecal calprotectin testing is considered experimental/investigational for all other indications because the safety and/or effectiveness of this service cannot be established by the available published peer-reviewed literature.
Molecular pathology testing using serological markers/laboratory tests for the diagnosis or management of IBD are considered experimental/investigational. There is a lack of scientific evidence that the use of these tests is likely to alter the diagnostic workup, the final diagnosis made, or the treatment provided for patients with suspected IBD.
Examples of serological markers/laboratory tests include: